Table 4.

Multivariable risk factors for oral HPV clearance among 459 participants with 917 oral HPV infections, by sex^a

	Infections in Men, n=472			Infections in Women, n=445
Characteristic at visit of first oral HPV detection	No. of cleared infections	Person- months	aHR (95% CI)	No. of cleared infections	Person- months	aHR (95% CI)
TNF-α concentration (pg/ml) b
Quartile 1	115	2,557	Ref	59	1,443	Ref
Quartile 2	77	3,593	0.56 (0.40-0.79)	69	1,869	0.97 (0.70-1.34)
Quartile 3	62	2,713	0.60 (0.44-0.82)	84	2,392	1.07 (0.76-1.49)
Quartile 4	46	2,432	0.52 (0.34-0.79)	81	3,264	0.76 (0.55-1.04)
	p for interaction=0.049
IL-2 concentration (pg/ml) c
Quartile 1	124	3,612	Ref	101	3,053	Ref
Quartile 2	39	1,868	0.66 (0.45-0.96)	33	1,243	0.90 (0.58-1.37)
Quartile 3	69	2,703	0.70 (0.52-0.93)	79	2,442	1.09 (0.82-1.47)
Quartile 4	65	2,906	0.69 (0.50-0.95)	79	2,223	1.15 (0.85-1.57)
	p for interaction=0.058
Infection type
Incident	140	2,908	Ref	148	2,480	Ref
Prevalent	160	8,388	0.52 (0.40-0.67)	146	6,494	0.45 (0.34-0.59)
Age (years)
<45	63	1,995	Ref	107	2,929	Ref
45-54	124	4,423	0.83 (0.61-1.12)	137	4,036	0.95 (0.74-1.22)
≥55	113	4,877	0.67 (0.48-0.92)	50	2,009	0.82 (0.58-1.15)
HIV and current CD4 cell count (cells/μL)
HIV uninfected	74	2,326	Ref	53	1,370	Ref
HIV infected, CD4≥500	124	4,386	0.89 (0.66-1.21)	93	3,157	0.78 (0.56-1.08)
HIV infected, CD4<500	102	4,584	0.87 (0.64-1.19)	148	4,447	0.92 (0.68-1.25)

^aTNF-α and IL-2 were each analyzed in separate multivariable models adjusting for infection type, age, and HIV status/CD4 count. Covariates shown are from the model with TNF-α. Bolding indicates adjusted hazard ratios (aHR) with p<0.05.

^bTNF-α quartiles: 0.0-2.56 (Q1), 2.57-3.58 (Q2), 3.59-4.93 (Q3), 4.94-19.33 (Q4).

^cIL-2 quartiles: 0.0-0.0 (Q1), 0.21-0.37 (Q2), 0.38-0.58 (Q3), 0.59-20.62 (Q4).